Kaveh Kousari, MD
Urology · Pennington, NJNPI 1407083199
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 96 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $808 and has fallen 97.6% since, to $19 in 2025. That places this record below the midpoint for urology clinicians in NJ, where the typical reported total is $2,095.
Across 96 payments — averaging $23.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$519
- Boston Scientific$253
- Myriad Genetic Laboratories, Inc.$214
- Olympus America Inc.$166
- Axonics, Inc.$121
- Photocure Inc$117
- plus $895 from 19 others
What the payments were for
- Food & beverage$2,23098%
- Education$552%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 11 | $519 |
| Boston Scientific | 10 | $253 |
| Myriad Genetic Laboratories, Inc. | 11 | $214 |
| Olympus America Inc. | 7 | $166 |
| Axonics, Inc. | 6 | $121 |
| Photocure Inc | 6 | $117 |
| Astellas Pharma US Inc | 4 | $110 |
| Procept Biorobotics Corporation | 2 | $108 |
| AbbVie | 7 | $101 |
| Sumitomo Pharma America, Inc. | 6 | $98 |
| Merck | 5 | $74 |
| Myovant Sciences Inc. | 5 | $71 |
| Teleflex LLC | 1 | $46 |
| Johnson & Johnson | 3 | $41 |
| Davol Inc. | 1 | $36 |
| Telix Pharmaceuticals | 2 | $35 |
| Foundation Medicine, Inc. | 1 | $28 |
| Laborie Medical Technologies Corp. | 1 | $24 |
| Hollister Incorporated | 1 | $23 |
| 180 Medical, Inc. | 1 | $21 |
| Pfizer | 1 | $17 |
| Calyxo, Inc. | 1 | $17 |
| Cook Medical LLC | 1 | $15 |
| AstraZeneca | 1 | $15 |
| Urovant Sciences Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$363
How this compares
$2,285 in reported general payments places this provider in the 50th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 49 | $45,988 |
| MyrbetriqMirabegron | 66 | $41,305 |
| Oxybutynin Chloride ErOxybutynin Chloride | 129 | $2,549 |
| Trospium Chloride | 28 | $2,401 |
| Tamsulosin Hcl | 137 | $2,354 |
| Tolterodine Tartrate ErTolterodine Tartrate | 15 | $1,356 |
| Finasteride | 79 | $1,222 |
| Solifenacin Succinate | 13 | $597 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 19 | $422 |
| Cephalexin | 16 | $62 |
| Oxycodone Hcl | 16 | $52 |
| Ciprofloxacin Hcl | 24 | $36 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 20 | $27 |
| Tramadol Hcl | 11 | $21 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $98 | $45,98849 claims |
| Astellas Pharma US IncMyrbetriq | $110 | $41,30566 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 401 urology providers in New Jersey.
Other urology in Pennington
- Michael StifelmanHackensack$1.4M
- Gordon BrownCherry Hill$1.3M
- Thomas MuellerLinwood$1.1M
- David SussmanLinwood$802K
- Michael IngberDenville$530K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Mutahar AhmedMaywood$414K
- Kevin GioiaRumson$143K
- Robert SimonCliffside Park$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.